Immutep (IMMP) stock climbed 11% Thursday after the company reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. Read more here.
Zacks Small Cap Research on MSN2h
AEMD: Oncology Trial Moves Forward as Patient Enrollments Begin, Positive on Cost Containment MeasuresAEMD READ THE FULL AEMD RESEARCH REPORT Patient enrollments begin for AEMD’s basket oncology trial Aethlon Medical (NASDAQ:AEMD) announced FY 2Q results and provided a business update yesterday. The ...
Immutep (IMMP) announces positive data from investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alpha (efti) in combination with KEYTRUDA and chemotherapy for first-line treatment ...
Immutep (IMMP) announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in ...
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...
(Reuters) -Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months ...
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... Akeso and Summit are leading the race, but BioNTech is well ...
Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback